Compare Lucid Group Inc (LCID) vs Mesoblast Limited (MESO) Price & Performance

Lucid Group (LCID) trades at $7.33, down 0.41% on the day, amid mixed technical signals and severe fundamental challenges. The stock shows a bullish moving average trend but bearish oscillators, with RSI at 70.77 suggesting overbought conditions. Financially, the company reported a net loss of $2.70 billion on $1.35 billion revenue in 2025, with negative margins across gross profit (-95.6%) and net income (-239.81%). Recent news highlights class-action lawsuits and bankruptcy rumors, though management denies financial distress.

The outlook remains highly speculative with significant execution and liquidity risks. Analyst consensus is cautious, with 66.7% hold ratings and a $10.50 price target implying limited upside. Investment appeal hinges on Lucid's ability to achieve profitability and scale production, but current financials and legal overhangs present substantial headwinds for near-term performance.

MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.

Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.